Avance Biosciences, Inc.

Avance Biosciences is excited to announce its participation in the upcoming SITC Conference, taking place from November 6-10, 2024, in Houston TX. This premier event is focused on improving outcomes for cancer patients by incorporating strategies based on basic and applied #cancer #immunotherapy.

Avance Biosciences is excited to announce its participation in the upcoming SITC Conference, taking place from November 6-10, 2024, in Houston TX. This premier event is focused on improving outcomes for cancer patients by incorporating strategies based on basic and applied #cancer #immunotherapy.

Avance Biosciences is excited to announce its participation in the upcoming Immunogenicity & Bioassay Summit, taking place from October 15 -18, 2024, in Washington DC. This is the #1 Immunogenicity & Bioassay Event in the U.S. https://lnkd.in/gpXTA-vB

Our team will showcase our cutting-edge expertise in #geneediting analysis, particularly focusing on on/off-target effects, which are crucial for the development of safe and effective #CRISPR-based therapies. Our comprehensive services, including GUIDE-Seq, rhAmpSeq?, and advanced amplicon sequencing, are designed to ensure the precision and reliability of gene editing technologies.

Avance Biosciences is heading to the 2nd CRISPR-Based Therapy Analytical Development Summit in Boston from September 17-19! Join us to explore our cutting-edge expertise in gene editing analysis, including GUIDE-Seq and rhAmpSeq?, and see how our innovative solutions ensure precise and reliable CRISPR therapies.

The groundbreaking #CRISPR-based gene therapy, exagamglogene autotemcel (exa-cel), will soon be available for those with severe beta-thalassaemia. This one-time treatment could potentially end the need for regular blood transfusions and marks a significant advancement in #genetherapy for this condition.

“The approval of this state-of-the-art #immunotherapy technology provides a critical new option for a patient population in need and demonstrates the FDA’s dedication to the advancement of beneficial #cancertreatments.” - FDA - Center for Biologics Evaluation and Research (CBER)

Two hallmark toxicities of chimeric antigen receptor (CAR) T-cell therapy may be rare after 2 weeks following infusion in patients with diffuse large B-cell lymphoma (DLBCL), supporting a shorter, more flexible toxicity monitoring period. #celltherapy #FDA #DLBCL

Avance Biosciences is excited to announce that our newly designed website is now live! Our new site features a clear and simplistic design, making it easy for current and potential customers to navigate and discover our comprehensive offerings for assay development, validation, and sample testing in compliance with FDA regulations. Visit us at www.avancebio.com. We greatly appreciate our marketing team's exceptional work on this project, completing the new website in just a couple of months. Even more so, we are incredibly proud of our laboratory and quality teams, along with all supporting crew, who over the past 14 years have built an impressive array of analytical and bioanalytical tools to support drug development and manufacturing activities!

Avance Biosciences? offers top-tier GLP & GMP compliant services in assay development, validation, & sample testing for biopharma. Visit our booth to explore how we support drug discovery, development, & manufacturing with precision & expertise.